-+ 0.00%
-+ 0.00%
-+ 0.00%

Quince Therapeutics to host virtual KOL event on PH-ILD, BOS treatment landscape and LAM-001

PUBT·09/17/2026 12:01:41
Listen to the news
Quince Therapeutics to host virtual KOL event on PH-ILD, BOS treatment landscape and LAM-001
  • Quince Therapeutics will host a virtual KOL event on Sept. 28, 2026, from 12:30-2:00 p.m. ET.
  • Discussion will cover treatment landscapes for PH-ILD and BOS, focusing on LAM-001, an inhaled rapamycin dry powder formulation in Phase 2 trials.
  • Presentations will include recently disclosed Phase 2a pulmonary hypertension data, plus updates on ongoing Phase 2 BOS and Phase 2b PH-ILD studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170800PRIMZONEFULLFEED9828576) on September 17, 2026, and is solely responsible for the information contained therein.